PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the Company is presenting at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society being held on October 12-15, 2014 in San Diego. Scheduled conference presentations include the following:
October 12, 2014 – A poster presentation titled, “Kinetics of DPC-mediated delivery of cholesterol-conjugated RNAi triggers and their subcellular processing in vivo,” will be presented by Christine Woodell, Ph.D., Group Leader
October 15, 2014 – An oral presentation titled, “Development of RNAi-based therapeutics using Dynamic Polyconjugate (DPC) delivery technology,” will be presented by David Lewis, Ph.D., Chief Scientific Officer
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadresearch.com/alerts.cfm.